Table 2.
Patients’ characteristics regarding plasma LRG without preoperative chemoradiation therapy
| Variables Data express as number (%) | Preoperative LRG high | Preoperative LRG low | P‐value |
|---|---|---|---|
| Gender | |||
| Male | 55% | 62% | 1.0000 |
| Female | 45% | 38% | |
| Location of pancreas | |||
| Head | 55% | 62% | 1.0000 |
| Body and tail | 45% | 38% | |
| Tumor size (mm) | 31.6 | 23.1 | .0555 |
| Histology | |||
| Well‐differentiated tubular adenocarcinoma | 0% | 8% | .5422 |
| Moderately | 77% | 92% | |
| Poorly | 23% | 0% | |
| UICC‐pT | |||
| pT1 | 11% | 8% | .6161 |
| pT2 | 0% | 15% | |
| pT3 | 89% | 77% | |
| UICC‐pN1 | 56% | 69% | .6656 |
| UICC‐M1 | 0% | 0% | N/A |
| UICC‐pStage | |||
| I | 11% | 23% | .6161 |
| II | 89% | 77% | |
| III | 0% | 0% | |
| IV | 0% | 0% | |
| Positive for microinvasion lymphatic system | 89% | 69% | .3602 |
| Positive for microinvasion to venous system | 56% | 47% | 1.0000 |
| Positive for microinvasion to nervous system | 89% | 92% | 1.0000 |
Values are expressed as mean ± SD or number (%). LRG, leucine‐rich alpha‐2‐glycoprotein; N/A, not applicable; UICC, Union for International Cancer Control.